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Topical suplatast tosilate (IPD) ameliorates 
Th2 cytokine-mediated dermatitis of caspase-1 
transgenic mice by downregulating interleukin-
4 and interleukin-5
Atopic dermatitis 
(AD) is a chronic 
i n f l a m m a t o r y 
skin disease asso-
ciated with over-
expressed Th2 
cytokines includ-
ing interleukin (IL)-4 and IL-5. Systemic administration of 
suplatast tosilate (IPD) is currently used to treat AD. We eval-
uated the effects of topical IPD using an AD mouse model. 
The skin manifestations and dermal mast cell infiltration in 
IPD-treated mice were suppressed, with a decrease in IL-
4 and IL-5 mRNA expression in skin as well as in spleen. 
Serum histamine, IgE and IL-18 levels were also decreased, 
suggesting the potential usefulness of topical IPD for the 
treatment of AD. Br J Dermatol 2005; 155:27–32.
Elevated serum levels of calcium-binding S100 
proteins A8 and A9 in psoriasis
Psoriatic skin is characterized by hyperproliferation and 
abnormal differentiation of keratinocytes. Among the dys-
regulated genes are members of the S100 family of calcium-
binding proteins including S100A8 and S100A9. Benoit et 
al. report elevated serum levels of S100A8 and S100A9 in 
patients with psoriasis that correlated with the clinical sever-
ity as reflected by the Psoriasis Area and Severity Index score. 
Keratinocytes were identified as the presumed source. These 
data suggest that 
levels of circulat-
ing S100A8 and 
S100A9 in psoria-
sis directly reflect 
pathological hyper-
proliferation and 
differentiation of 
psoriatic keratino-
cytes. Furthermore, 
they imply extracellular systemic functions of S100 molecules 
in the context of psoriasis. Br J Dermatol 2006; 155:62–66.
Rumex japonicus Houtt. on atopic dermatitis in 
NC/Nga mice
Although patients with atopic dermatitis (AD) may benefit 
from herbal therapy, the possibility of hepatic toxic effects 
or other side-effects remains a concern. Lee et al. report that 
oral administration of Rumex japonicus Houtt. (RJH), a herb 
used in Eastern countries for the management of cutaneous 
diseases including AD, inhibits the development of AD-like 
symptoms in NC/Nga mice with no apparent side-effects, 
by suppressing the 
Th2 cell response. 
It thus seems that 
RJH treatment may 
provide effective 
alternative or com-
plementary therapy 
for patients with AD. 
Br J Dermatol 2006; 
155:33–38.
